HLA-A and neoplasm: In our study, we identified an HLA-A*11:01-binding immunogenic neoantigen peptide P1 (RTEDEVYNSNK) derived from CLDN18-ARHGAP gene fusion and successfully induced NRT cells with strong tumor-killing ability in both cell lines and mouse models with CLDN18-ARHGAP gene fusion.